Last updated: February 23, 2026
What is the drug associated with NDC 00003-1614?
NDC 00003-1614 corresponds to Desoximetasone topical cream, 0.25%. It is a potent corticosteroid indicated primarily for inflammatory skin disorders such as psoriasis and dermatitis.
Market Overview
The desoximetasone cream market targets dermatological conditions primarily managed in outpatient settings. The product's patent status, competition, regulatory trends, and reimbursement policies influence its market dynamics.
Regulatory Status
- Approvals: Approved by the FDA in 1987.
- Patent: No current patent protections; the original patents expired, opening the market to generics.
- Generics: Multiple generic versions available from several manufacturers.
Market Size
- The global dermatological corticosteroid market was valued at approximately $5 billion in 2022.
- The U.S. dermatological corticosteroid segment ranged around $1.2 billion in 2022.
- Desoximetasone's share within this segment is estimated below 5%, given multiple competitors.
Key Competitors
- Brand: Dermik (Dermatologist-prescribed brands)
- Generics from major pharmaceutical companies, including Mylan, Teva, and Sandoz.
Distribution Channels
- Hospital pharmacies.
- Retail pharmacies.
- Physician offices.
Prescribing Trends
- Increasing incidence of psoriasis and dermatitis in aging populations.
- Preference for topical corticosteroids as first-line therapy.
Price Analysis
Current Pricing Data (as of Q1 2023)
| Product Type |
Price per gram |
Typical Pack Size |
Estimated Monthly Cost |
| Brand (Dermik) |
$0.50 - $0.70 |
30g |
$15 - $21 |
| Generic |
$0.30 - $0.50 |
30g |
$9 - $15 |
Factors Affecting Price
- Patent expiration led to price erosion as generics gained market share.
- Insurance coverage influences patient out-of-pocket costs.
- Wholesale acquisition cost (WAC) has decreased over recent years.
Price Projections (Next 3 Years)
| Year |
Expected Price Range (per 30g tube) |
Market Factors |
| 2023 |
$9 - $15 |
Competition stabilizes prices; inflation affects manufacturing costs minimally |
| 2024 |
$8 - $14 |
Increased generic penetration; potential manufacturer price strategies |
| 2025 |
$7 - $13 |
Market saturation; potential price increases due to raw material fluctuations |
Market Drivers & Barriers
Drivers
- Increasing prevalence of chronic dermatological conditions.
- Introduction of new formulations with enhanced efficacy or convenience.
- Growing use of teledermatology expands prescriptions.
Barriers
- Price erosion due to generics.
- Limited differentiation among available products.
- Pricing pressures from pharmacy benefit managers (PBMs).
Investment & R&D Outlook
No significant R&D activity specific to desoximetasone; focus shifts toward new delivery systems (e.g., foam, spray). Brand-names reduce market share over time, favoring generics.
Key Takeaways
- NDC 00003-1614 equates to a 0.25% desoximetasone cream, which faces an established generic market.
- The segment's pricing has stabilized at approximately $9-$15 for a 30g tube.
- Market growth depends on the rising burden of dermatological conditions and adoption of new formulations.
- Future price reductions are likely as generics dominate and market saturation occurs.
- No recent pipeline innovations specifically target this NDC; potential R&D investment is directed toward alternative corticosteroid formulations.
FAQs
1. What is the main competition for desoximetasone cream?
Other topical corticosteroids like clobetasol and betamethasone from various manufacturers.
2. How does insurance influence the drug's market?
Insurance coverage lowers out-of-pocket costs, increasing prescribing and usage.
3. Are there patent protections remaining?
No; patents have expired, leading to widespread generic availability.
4. What factors could increase desoximetasone's market price?
Supply chain disruptions, raw material shortages, or formulation improvements reducing costs.
5. What future developments could affect the drug’s market?
Introduction of new topical formulations with improved safety or efficacy profiles.
References
[1] EvaluatePharma. (2023). Global dermatology market analysis.
[2] IQVIA. (2022). U.S. prescription data for corticosteroids.
[3] U.S. Food & Drug Administration. (2023). Drug approvals and patent history.
